WINTON GROUP Ltd Has $2.86 Million Position in Becton, Dickinson and Company (BDX)

WINTON GROUP Ltd boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 18.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,612 shares of the medical instruments supplier’s stock after acquiring an additional 2,289 shares during the quarter. WINTON GROUP Ltd’s holdings in Becton, Dickinson and were worth $2,863,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Westwood Holdings Group Inc. lifted its holdings in shares of Becton, Dickinson and by 24.2% during the 2nd quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after buying an additional 205,721 shares during the period. Colony Group LLC lifted its holdings in shares of Becton, Dickinson and by 2.1% during the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after buying an additional 239 shares during the period. State Street Corp lifted its holdings in shares of Becton, Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares during the period. Peapack Gladstone Financial Corp lifted its holdings in shares of Becton, Dickinson and by 1.3% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after buying an additional 453 shares during the period. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Becton, Dickinson and by 35.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock valued at $8,447,000 after buying an additional 11,300 shares during the period. 88.60% of the stock is currently owned by institutional investors and hedge funds.

In other Becton, Dickinson and news, insider Stephen Sichak sold 11,787 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the sale, the insider now owns 14,038 shares in the company, valued at approximately $2,814,057.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) opened at $226.33 on Friday. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. The company has a market capitalization of $51,170.00, a price-to-earnings ratio of 24.05, a PEG ratio of 1.79 and a beta of 1.04. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $229.68.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. Becton, Dickinson and’s revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.12 EPS. research analysts anticipate that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.33%. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. Becton, Dickinson and’s dividend payout ratio is 62.80%.

BDX has been the topic of several research analyst reports. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a report on Tuesday, October 31st. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a report on Tuesday, September 12th. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Finally, Cowen reissued a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a report on Monday, August 14th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $217.08.

COPYRIGHT VIOLATION NOTICE: “WINTON GROUP Ltd Has $2.86 Million Position in Becton, Dickinson and Company (BDX)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/02/winton-group-ltd-has-2-86-million-position-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply